BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Geem D, Harusato A, Flannigan K, Denning TL. Harnessing regulatory T cells for the treatment of inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:1409-1418. [PMID: 25793328 DOI: 10.1097/mib.0000000000000343] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Candia E, Reyes P, Covian C, Rodriguez F, Wainstein N, Morales J, Mosso C, Rosemblatt M, Fierro JA. Single and combined effect of retinoic acid and rapamycin modulate the generation, activity and homing potential of induced human regulatory T cells. PLoS One 2017;12:e0182009. [PMID: 28746369 DOI: 10.1371/journal.pone.0182009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
2 Hossein-Khannazer N, Torabi S, Hosseinzadeh R, Shahrokh S, Asadzadeh Aghdaei H, Memarnejadian A, Kadri N, Vosough M. Novel cell-based therapies in inflammatory bowel diseases: the established concept, promising results. Hum Cell 2021;34:1289-300. [PMID: 34057700 DOI: 10.1007/s13577-021-00560-w] [Reference Citation Analysis]
3 Zhao HW, Yue YH, Han H, Chen XL, Lu YG, Zheng JM, Hou HT, Lang XM, He LL, Hu QL, Dun ZQ. Effect of toll-like receptor 3 agonist poly I:C on intestinal mucosa and epithelial barrier function in mouse models of acute colitis. World J Gastroenterol 2017;23:999-1009. [PMID: 28246473 DOI: 10.3748/wjg.v23.i6.999] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
4 Abo H, Flannigan KL, Geem D, Ngo VL, Harusato A, Denning TL. Combined IL-2 Immunocomplex and Anti-IL-5 mAb Treatment Expands Foxp3+ Treg Cells in the Absence of Eosinophilia and Ameliorates Experimental Colitis. Front Immunol 2019;10:459. [PMID: 30930900 DOI: 10.3389/fimmu.2019.00459] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
5 Porter RJ, Andrews C, Brice DP, Durum SK, McLean MH. Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease? Inflamm Bowel Dis 2018;24:2123-34. [PMID: 30020451 DOI: 10.1093/ibd/izy230] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
6 Creyns B, Cremer J, Hoshino T, Geboes K, de Hertogh G, Ferrante M, Vermeire S, Ceuppens JL, Van Assche G, Breynaert C. Fibrogenesis in Chronic DSS Colitis is Not Influenced by Neutralisation of Regulatory T Cells, of Major T Helper Cytokines or Absence of IL-13. Sci Rep 2019;9:10064. [PMID: 31296924 DOI: 10.1038/s41598-019-46472-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Zhang S, Langer R, Traverso G. Nanoparticulate Drug Delivery Systems Targeting Inflammation for Treatment of Inflammatory Bowel Disease. Nano Today 2017;16:82-96. [PMID: 31186671 DOI: 10.1016/j.nantod.2017.08.006] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 14.0] [Reference Citation Analysis]
8 Maatouk M, Mustapha N, Mokdad-Bzeouich I, Chaaban H, Abed B, Iaonnou I, Ghedira K, Ghoul M, Ghedira LC. Thermal treatment of luteolin-7-O-β-glucoside improves its immunomodulatory and antioxidant potencies. Cell Stress Chaperones 2017;22:775-85. [PMID: 28578499 DOI: 10.1007/s12192-017-0808-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
9 Tai Y, Wang Q, Korner H, Zhang L, Wei W. Molecular Mechanisms of T Cells Activation by Dendritic Cells in Autoimmune Diseases. Front Pharmacol 2018;9:642. [PMID: 29997500 DOI: 10.3389/fphar.2018.00642] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 18.7] [Reference Citation Analysis]
10 Grigg JB, Sonnenberg GF. Host-Microbiota Interactions Shape Local and Systemic Inflammatory Diseases. J Immunol 2017;198:564-71. [PMID: 28069751 DOI: 10.4049/jimmunol.1601621] [Cited by in Crossref: 54] [Cited by in F6Publishing: 41] [Article Influence: 13.5] [Reference Citation Analysis]
11 Lee SH, Kwon JE, Cho ML. Immunological pathogenesis of inflammatory bowel disease. Intest Res. 2018;16:26-42. [PMID: 29422795 DOI: 10.5217/ir.2018.16.1.26] [Cited by in Crossref: 128] [Cited by in F6Publishing: 107] [Article Influence: 42.7] [Reference Citation Analysis]
12 Xiao W, Yin M, Wu K, Lu G, Deng B, Zhang Y, Qian L, Jia X, Ding Y, Gong W. High-dose wogonin exacerbates DSS-induced colitis by up-regulating effector T cell function and inhibiting Treg cell. J Cell Mol Med 2017;21:286-98. [PMID: 27641629 DOI: 10.1111/jcmm.12964] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
13 Mizui M, Tsokos GC. Targeting Regulatory T Cells to Treat Patients With Systemic Lupus Erythematosus. Front Immunol 2018;9:786. [PMID: 29755456 DOI: 10.3389/fimmu.2018.00786] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 8.7] [Reference Citation Analysis]
14 Singh RP, Bischoff DS. Sex Hormones and Gender Influence the Expression of Markers of Regulatory T Cells in SLE Patients. Front Immunol 2021;12:619268. [PMID: 33746959 DOI: 10.3389/fimmu.2021.619268] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]